Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Net Cash Flow (2022 - 2025)

CervoMed's Net Cash Flow history spans 9 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 149.29% year-over-year to $1.1 million; the TTM value through Sep 2025 reached -$2.9 million, up 94.1%, while the annual FY2024 figure was $1.2 million, 67.38% down from the prior year.
  • Net Cash Flow for Q3 2025 was $1.1 million at CervoMed, up from -$6.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $10.2 million in Q3 2022 and bottomed at -$42.8 million in Q2 2024.
  • The 4-year median for Net Cash Flow is -$1.4 million (2024), against an average of -$4.0 million.
  • The largest annual shift saw Net Cash Flow tumbled 273.17% in 2024 before it surged 205.52% in 2025.
  • A 4-year view of Net Cash Flow shows it stood at $6.3 million in 2022, then plummeted by 141.73% to -$2.6 million in 2023, then skyrocketed by 147.72% to $1.3 million in 2024, then fell by 11.08% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Net Cash Flow are $1.1 million (Q3 2025), -$6.8 million (Q2 2025), and $1.5 million (Q1 2025).